<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636127</url>
  </required_header>
  <id_info>
    <org_study_id>2015-37</org_study_id>
    <nct_id>NCT02636127</nct_id>
  </id_info>
  <brief_title>Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis</brief_title>
  <official_title>Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic Sclerosis (SSc) is an auto-immune systemic disease characterized by vascular damage,&#xD;
      cutaneous and visceral fibrosis and a dysimmune condition.&#xD;
&#xD;
      Therapies in this disease remain insufficient and the complications resulting from organs&#xD;
      involvement lead to strong morbi-mortality.The dermic infiltrate of the patients includes a&#xD;
      strong proportion of Tcells. T cells and Natural Killer (NK) cells are potentially involved&#xD;
      in the vascular damage of the SSc. However mechanisms at the onset of this endothelial&#xD;
      cytotoxicity and its impact on the capacities of regeneration of the endothelial tissue&#xD;
      remain poorly understood. Fractalkine is at the same time an endothelial membrane-bound&#xD;
      adhesion molecule and a chemokine which is able to bind CX3CR1 expressed by the immune&#xD;
      populations. The purpose of the project is to define the role displayed by cytotoxic,&#xD;
      circulating immune populations of SSc patients in endothelial cytotoxicity as well as the&#xD;
      role of the axis Fractalkine / CX3CR1 in mediating the interactions between the immune&#xD;
      cytotoxic cells and the endothelium.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2015</start_date>
  <completion_date type="Actual">July 8, 2018</completion_date>
  <primary_completion_date type="Actual">July 21, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood sample will be done for dosage of Fractalkine in the serum</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood sample for functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Scleroderma, Systemic</condition>
  <arm_group>
    <arm_group_label>Systemic Sclerosis (SSc) patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 patients whose diagnosis of SSc is made according to the revised ACR/EULAR ( American College of Rheumatology ) criteria 2013 will be recruited and blood samples will be obtained</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>15 healthy patients will be recruited and blood samples will be obtained</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>one blood sample will be done for dosage and role of Fractalkine in the serum.&#xD;
- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release.</description>
    <arm_group_label>Systemic Sclerosis (SSc) patient</arm_group_label>
    <arm_group_label>healthy patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients affected by SSc of more than 18 years&#xD;
&#xD;
          -  Healthy patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impossibility to take some blood&#xD;
&#xD;
          -  Current infection&#xD;
&#xD;
          -  Ongoing cancer&#xD;
&#xD;
          -  chemotherapy or a current radiotherapy&#xD;
&#xD;
          -  pregnant or breast-feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte GRANEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique HÃ´pitaux de Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

